title: Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia.
abstract: Graft-versus-host disease (GVHD) is a severe disorder and despite therapeutic efforts to decrease its distressing clinical manifestations, treatment is still not optimal. Here we report the results of studies, in which the purine analogue, fludarabine phosphate, was used in an attempt to modify and decrease GVHD after stem cell transplantation, across major histocompatibility barriers for murine leukemia. B-cell leukemia (BCL-1) bearing (BALB/c x C57BL/6) F1 mice received two cycles of fludarabine (0.8 mg/kg) for 5 days every 2 weeks, followed by 400 mg/kg cyclophosphamide i.p. Animals were then transplanted with C57BL/6 precursor cells and the development of leukemia and extent of GVHD was monitored both clinically and histopathologically. In the fludarabine-treated group, only nine of 28 (32%) mice developed leukemia, compared to 25 of 33 (76%) of control animals (P=0.0006 ). Mice treated with fludarabine-containing regimens prior to transplantation also had much less GVHD both clinically and at autopsy, while graft-versus-leukemia appeared to be augmented in the same animals.
authors.affiliation: Department of Bone Marrow Transplantation and Cancer Immunology, Jerusalem, Israel.
authors.forename: L
authors.initials: L
authors.lastname: Weiss
authors.forename: A
authors.initials: A
authors.lastname: Abdul-Hai
authors.forename: R
authors.initials: R
authors.lastname: Or
authors.forename: G
authors.initials: G
authors.lastname: Amir
authors.forename: A
authors.initials: A
authors.lastname: Polliack
mesh_terms: D000818:Animals; D017209:Apoptosis; D003433:Crosses, Genetic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006086:Graft vs Host Disease / Q000473:pathology / Q000517:prevention & control*; D015448:Leukemia, B-Cell / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D012867:Skin / Q000473:pathology; D013154:Spleen / Q000473:pathology; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine